Biogen Raises Full-Year Revenue Guidance as New Drug Business Surpasses Multiple Sclerosis Business for the First Time
nashnova research
Biogen posted Q2 adjusted EPS of $3.60, beating estimates by over $1.57, on revenue of $2.7 billion — up 3.8% year-on-year. The company flipped its full-year revenue outlook from mid-single-digit decline to mid-single-digit growth, marking the first quarter where newer drugs outsold its legacy MS portfolio.
Why did this quarter surprise the Street?
Adjusted EPS came in at $3.60 — $1.57 above consensus, nearly double what analysts expected.
Revenue hit $2.7 billion, up 3.8% year-on-year, beating estimates by $240 million.
This means → Biogen didn't just "not disappoint." It delivered positive growth in a quarter the market had written off.
How did newer drugs overtake the legacy business?
Biogen closed its $5.6 billion acquisition of Apellis Pharmaceuticals in May, adding Syfovre (for an immune-driven blinding disease) and Empaveli (for rare blood and kidney disorders). The two drugs contributed roughly $128 million in revenue for the partial quarter.
Postpartum-depression treatment Zurzuvae grew 53% year-on-year to $71 million; rare-disease drug Skyclarys posted about $168 million, ahead of analyst estimates.
Alzheimer's drug Leqembi (co-marketed with Eisai) rose 15% to $184 million, roughly in line with expectations.
In plain terms = Biogen shifted from a one-legged revenue model — MS drugs — to a multi-legged one through acquisitions and organic launches. Combined, the newer portfolio now outsells the legacy franchise.
Why did guidance move in opposite directions?
Revenue guidance raised: flipped from "mid-single-digit percentage decline" to "mid-single-digit percentage growth" — a full directional reversal.
EPS guidance cut: lowered from $14.25–$15.25 to $12–$13, driven by R&D costs, milestone payments, and financing expenses tied to the Apellis deal.
This means → Biogen is trading near-term profit for a new revenue engine. Management noted that stripping out acquisition-related items, underlying earnings guidance actually rose by $0.60.
What does the market watch next?
CEO Christopher Viehbacher announced a second deal in June — up to $1 billion for private immunology developer RayThera — expanding into nephrology and immunology.
This reflects a clear strategic bet: the MS franchise is in irreversible decline, so Biogen must build new growth pillars through M&A.
Put simply = whether the newer drugs can sustain volume growth and earn back the acquisition spend is the core test for when Biogen's earnings trajectory recovers.
市场有风险，内容仅供研究参考，不构成投资建议。